^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    NovoPM™ 2.0

    Company:
    Novogene
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    The Novogene Precision Medicine 2.0 (NovoPM™ 2.0) comprehensive genomic profiling test for solid tumors is a hyphenate sequencing (NGS)-based assay that analyzes 484 genes for clinically important alterations at the DNA level. NovoPMTM 2.0 interrogates the complete coding regions of 468 genes and the introns of 43 genes. It can detect all four types of genomic abnormalities(SNV, InDel, CNV and Fusion) and also generate results (TMB, bTMB and MSI）that can help guide cancer immunotherapies.
    Cancer:
    Breast Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor
    Gene:
    ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2)
    See More ...
    Drug:
    Alecensa (alectinib), Alunbrig (brigatinib), Braftovi (encorafenib), Erbitux (cetuximab), Gilotrif (afatinib), Herceptin (trastuzumab), Keytruda (pembrolizumab), Lorbrena (lorlatinib), Lynparza (olaparib), Mekinist (trametinib), Mektovi (binimetinib), Nerlynx (neratinib), Opdivo (nivolumab), Perjeta (pertuzumab), Piqray (alpelisib), Rozlytrek (entrectinib), Rubraca (rucaparib), Stivarga (regorafenib), Tafinlar (dabrafenib), Tagrisso (osimertinib), Talzenna (talazoparib), Tecentriq (atezolizumab), Vectibix (panitumumab), Vitrakvi (larotrectinib), Xalkori (crizotinib), Yervoy (ipilimumab), Zelboraf (vemurafenib), Zykadia (ceritinib), erlotinib, gefitinib, lapatinib
    Method:
    Next-Generation Sequencing (NGS)